APOC3
Apolipoprotein C-III
As of the edition of 20 October 2026, APOC3 (apolipoprotein C-III, UniProt P02656) has 5 drugs tested at it and 5 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02656
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 1
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Heart and blood vessels; Skin and connective tissue
- Registered trials of its drugs
- 23
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Olezarsen | Marketed | Phase 3 | none listed |
| Volanesorsen | Marketed | Phase 3 | none listed |
| RBD5044 | Active | Phase 2 | none listed |
| STT-5058 | Stopped | Phase 1 | none listed |
| Olezarsen sodium | Marketed | No phase stated | Ends 2034 |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Swedish Orphan Biovitrum | Route B |
| Staten Biotechnology | Route A |
The other 3 companies at APOC3
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at APOC3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.